We are live on
!
Find out more
6CM
683 Capital Management Portfolio holdings
AUM
$1.92B
1-Year Est. Return
85.52%
This Fund
S&P 500
This Quarter
Est. Return
+21.28%
1 Year Est. Return
+85.52%
3 Year Est. Return
+282.16%
5 Year Est. Return
+254.87%
10 Year Est. Return
+3,288.81%
AUM
$2.3B
AUM Growth
+$384M
(+20%)
Cap. Flow
+$216M
Cap. Flow
% of AUM
9.39%
Top 10 Holdings %
Top 10 Hldgs %
49.4%
Holding
255
New
116
Increased
33
Reduced
43
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Kaspi.kz JSC
KSPI
|
+$20M |
| 2 |
MREO
Mereo BioPharma
MREO
|
+$19.3M |
| 3 |
Becton Dickinson
BDX
|
+$17.1M |
| 4 |
SUNC
SunocoCorp LLC
SUNC
|
+$11.8M |
| 5 |
Molina Healthcare
MOH
|
+$8.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Western Digital
WDC
|
+$29.7M |
| 2 |
uniQure
QURE
|
+$26.4M |
| 3 |
Eli Lilly
LLY
|
+$21.8M |
| 4 |
BridgeBio Pharma
BBIO
|
+$19.6M |
| 5 |
SNDK
Sandisk
SNDK
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.71% |
| 2 | Financials | 6.94% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Industrials | 3.7% |
| 5 | Technology | 3.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Taylor Devices
TAYD
$170M
| $606K | 0.03% |
+10,371
| New | +$503K |
|
177
Black Diamond Therapeutics
BDTX
$103M
| $603K | 0.03% |
+247,958
| New | +$878K |
|
|
DFDV
178
DeFi Development Corp
DFDV
$84.3M
| $596K | 0.03% |
+117,990
| New | +$1.08M |
|
179
Stoneridge
SRI
$211M
| $589K | 0.03% |
+101,765
| New | +$640K |
|
180
NeoVolta
NEOV
$158M
| $589K | 0.03% |
+193,798
| New | +$818K |
|
|
IMDX
181
Insight Molecular Diagnostics
IMDX
$161M
| $579K | 0.03% |
+77,204
| New | +$436K |
|
|
LHAI
182
Linkhome Holdings
LHAI
$13.6M
| $573K | 0.02% |
+75,000
| New | +$802K |
|
183
Genelux
GNLX
$113M
| $572K | 0.02% |
+131,084
| New | +$708K |
|
184
CALL
MoonLake Immunotherapeutics
MLTX
$1.49B
| $547K | 0.02% |
+41,500
| New | +$490K |
|
185
Twin Disc
TWIN
$343M
| $533K | 0.02% |
+31,967
| New | +$495K |
|
|
AIFC
186
AI Financial Corp
AIFC
$58.9M
| $528K | 0.02% |
+480,308
| New | +$925K |
|
|
RDNW
187
RideNow Group
RDNW
$259M
| $526K | 0.02% |
+95,304
| New | +$445K |
|
188
Intellicheck
IDN
$77.2M
| $514K | 0.02% |
+76,895
| New | +$434K |
|
189
Microbot Medical
MBOT
$124M
| $512K | 0.02% |
+256,033
| New | +$606K |
|
190
Playboy Inc
PLBY
$134M
| $492K | 0.02% |
+261,780
| New | +$428K |
|
|
LGCY
191
Legacy Education Inc
LGCY
$152M
| $472K | 0.02% |
+46,296
| New | +$446K |
|
|
ONL
192
Orion Office REIT
ONL
$151M
| $470K | 0.02% |
+208,134
| New | +$491K |
|
193
CareCloud
CCLD
$108M
| $467K | 0.02% |
+159,761
| New | +$505K |
|
194
Coya Therapeutics
COYA
$107M
| $465K | 0.02% |
+80,128
| New | +$487K |
|
195
Elicio Therapeutics
ELTX
$83.8M
| $449K | 0.02% |
+56,442
| New | +$512K |
|
|
NTHI
196
NeOnc Technologies
NTHI
$90.8M
| $442K | 0.02% |
+53,476
| New | +$502K |
|
|
GPMT
197
Granite Point Mortgage Trust
GPMT
$71.9M
| $440K | 0.02% |
+183,150
| New | +$491K |
|
198
Apyx Medical
APYX
$174M
| $436K | 0.02% |
+124,506
| New | +$434K |
|
199
Inovio Pharmaceuticals
INO
$70M
| $433K | 0.02% |
+248,790
| New | +$548K |
|
200
BTCS Inc
BTCS
$54.8M
| $428K | 0.02% |
+161,992
| New | +$585K |
|
Similar funds
QOP
RIL
MC
RCAG
BOH
DCM
CC
IAN
683 Capital Management's Q4 2025 Portfolio in Review
As of Q4 2025, 683 Capital Management held 255 positions worth $2.3B, up 20% from $1.91B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
683 Capital Management deployed $216M of net new capital in Q4 2025, opening 116 new positions and adding to 33 existing holdings. Its largest new stake was Kaspi.kz JSC: 265,000 shares worth $20.7M.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 23% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Western Digital, an estimated $29.7M trimmed.
- 683 Capital Management's largest Q4 2025 buy was Kaspi.kz JSC: 265,000 shares worth $20.7M.
- 683 Capital Management added most to Mereo BioPharma in Q4 2025, an estimated $19.3M increase.
- 683 Capital Management's biggest Q4 2025 reduction was Western Digital, cutting an estimated $29.7M.
- 683 Capital Management fully exited Eli Lilly in Q4 2025, selling an estimated $21.8M.
- 683 Capital Management's ten largest holdings make up 49% of its $2.3B portfolio in Q4 2025.
- 683 Capital Management opened 116 new positions and closed 21 in Q4 2025.
- 683 Capital Management's portfolio value rose 20% quarter-over-quarter to $2.3B.
Based on 683 Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.